Ontology type: schema:ScholarlyArticle Open Access: True
2022-04-12
AUTHORSKazuya Takeda, Toru Sakayauchi, Masaki Kubozono, Yu Katagiri, Rei Umezawa, Takaya Yamamoto, Yojiro Ishikawa, Noriyoshi Takahashi, Yu Suzuki, Keita Kishida, Keiichi Jingu
ABSTRACTBackgroundPalliative radiotherapy for gastric cancer bleeding has been reported to be a safe and effective treatment, but predictive factors for achievement of hemostasis and overall survival have not been established.MethodsIn this retrospective study, 120 courses of palliative radiotherapy for gastric cancer bleeding in 117 patients in 4 institutes in Japan were reviewed with approval of the ethical committee in each institute. The rate of achieving hemostasis was evaluated by 50% or more reduction of red blood cell transfusion before and after the start of radiotherapy, elevation of blood hemoglobin concentration in a period of 4 weeks from the start of radiotherapy or improvement of subjective or objective clinical symptoms in a period of 4 weeks from the start of radiotherapy. Predictive factors for overall survival and achieving hemostasis were investigated with the Cox hazards model.ResultsThe median overall survival period was 3.7 months. Multivariate analysis showed that absence of metastatic disease, higher biological effective dose, higher serum albumin level, lower blood urea nitrogen level and lower neutrophil-to-lymphocyte ratio (NLR) were associated with longer overall survival. Elevation of hemoglobin concentration in a period of 4 weeks from the start of radiotherapy (mean concentration: 8.2 g/dL vs. 8.9 g/dL, p = 0.006) and decrease in the amount of red cell transfusion from a 4-week period before to a 4-week period after the start of radiotherapy (mean amount: 716 mL vs. 230 mL, p < 0.0001) were observed. The overall rate of achievement of hemostasis was 59.6%. In multivariate analysis, higher biological effective dose was associated with achievement of hemostasis. Grade 2 or higher acute adverse effects related to radiotherapy were observed in 17.5% of cases in 120 treatment courses. Six cases (5.0%) had grade 3 or 4 adverse effects including gastric penetration in 1 patient and anorexia requiring total parental nutrition in 3 patients. No grade 5 adverse effects were observed.ConclusionsPalliative radiotherapy for gastric cancer bleeding seems to be an effective and safe treatment strategy. Higher treatment dose was associated with longer overall survival and a hemostatic effect. Some hematological parameters may predict overall survival, and they would be helpful for deciding the treatment strategy. More... »
PAGES52
http://scigraph.springernature.com/pub.10.1186/s12904-022-00943-2
DOIhttp://dx.doi.org/10.1186/s12904-022-00943-2
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1147049122
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/35413824
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Clinical Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Oncology and Carcinogenesis",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Gastrointestinal Hemorrhage",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Hemoglobins",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Palliative Care",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Retrospective Studies",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Stomach Neoplasms",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Department of Radiation Oncology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, Japan",
"id": "http://www.grid.ac/institutes/grid.69566.3a",
"name": [
"Department of Radiation Oncology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, Japan"
],
"type": "Organization"
},
"familyName": "Takeda",
"givenName": "Kazuya",
"id": "sg:person.010025651231.08",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010025651231.08"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Radiation Oncology, Osaki City Hospital, 3-8-1 Furukawa Honami, Osaki, Miyagi, Japan",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Department of Radiation Oncology, Osaki City Hospital, 3-8-1 Furukawa Honami, Osaki, Miyagi, Japan"
],
"type": "Organization"
},
"familyName": "Sakayauchi",
"givenName": "Toru",
"id": "sg:person.0653677346.82",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653677346.82"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Radiation Oncology, Miyagi Prefecture Cancer Center, 47-1 Shiote Nodayama, Medeshima, Natori, Miyagi, Japan",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Department of Radiation Oncology, Miyagi Prefecture Cancer Center, 47-1 Shiote Nodayama, Medeshima, Natori, Miyagi, Japan"
],
"type": "Organization"
},
"familyName": "Kubozono",
"givenName": "Masaki",
"id": "sg:person.01247542047.45",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01247542047.45"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Radiation Oncology, Ishinomaki Red Cross Hospital, 71 Nishimichishita, Hebita, Ishinomaki, Miyagi, Japan",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Department of Radiation Oncology, Ishinomaki Red Cross Hospital, 71 Nishimichishita, Hebita, Ishinomaki, Miyagi, Japan"
],
"type": "Organization"
},
"familyName": "Katagiri",
"givenName": "Yu",
"id": "sg:person.01276326705.38",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01276326705.38"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Radiation Oncology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, Japan",
"id": "http://www.grid.ac/institutes/grid.69566.3a",
"name": [
"Department of Radiation Oncology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, Japan"
],
"type": "Organization"
},
"familyName": "Umezawa",
"givenName": "Rei",
"id": "sg:person.0753341500.49",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0753341500.49"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Radiation Oncology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, Japan",
"id": "http://www.grid.ac/institutes/grid.69566.3a",
"name": [
"Department of Radiation Oncology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, Japan"
],
"type": "Organization"
},
"familyName": "Yamamoto",
"givenName": "Takaya",
"id": "sg:person.0703105052.65",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0703105052.65"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Radiation Oncology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, Japan",
"id": "http://www.grid.ac/institutes/grid.69566.3a",
"name": [
"Department of Radiation Oncology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, Japan"
],
"type": "Organization"
},
"familyName": "Ishikawa",
"givenName": "Yojiro",
"id": "sg:person.01045651705.48",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01045651705.48"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Radiation Oncology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, Japan",
"id": "http://www.grid.ac/institutes/grid.69566.3a",
"name": [
"Department of Radiation Oncology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, Japan"
],
"type": "Organization"
},
"familyName": "Takahashi",
"givenName": "Noriyoshi",
"id": "sg:person.01240722426.42",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01240722426.42"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Radiation Oncology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, Japan",
"id": "http://www.grid.ac/institutes/grid.69566.3a",
"name": [
"Department of Radiation Oncology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, Japan"
],
"type": "Organization"
},
"familyName": "Suzuki",
"givenName": "Yu",
"id": "sg:person.010746032124.68",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010746032124.68"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Radiation Oncology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, Japan",
"id": "http://www.grid.ac/institutes/grid.69566.3a",
"name": [
"Department of Radiation Oncology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, Japan"
],
"type": "Organization"
},
"familyName": "Kishida",
"givenName": "Keita",
"id": "sg:person.015230711520.98",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015230711520.98"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Radiation Oncology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, Japan",
"id": "http://www.grid.ac/institutes/grid.69566.3a",
"name": [
"Department of Radiation Oncology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, Japan"
],
"type": "Organization"
},
"familyName": "Jingu",
"givenName": "Keiichi",
"id": "sg:person.01214741646.61",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01214741646.61"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1038/bjc.1991.62",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1056443284",
"https://doi.org/10.1038/bjc.1991.62"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/bjc.1992.196",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1007010292",
"https://doi.org/10.1038/bjc.1992.196"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s10388-018-0612-1",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1101778605",
"https://doi.org/10.1007/s10388-018-0612-1"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1186/s12916-020-01817-1",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1132773799",
"https://doi.org/10.1186/s12916-020-01817-1"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s10120-021-01254-w",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1141419997",
"https://doi.org/10.1007/s10120-021-01254-w"
],
"type": "CreativeWork"
}
],
"datePublished": "2022-04-12",
"datePublishedReg": "2022-04-12",
"description": "BackgroundPalliative radiotherapy for gastric cancer bleeding has been reported to be a safe and effective treatment, but predictive factors for achievement of hemostasis and overall survival have not been established.MethodsIn this retrospective study, 120 courses of palliative radiotherapy for gastric cancer bleeding in 117 patients in 4 institutes in Japan were reviewed with approval of the ethical committee in each institute. The rate of achieving hemostasis was evaluated by 50% or more reduction of red blood cell transfusion before and after the start of radiotherapy, elevation of blood hemoglobin concentration in a period of 4\u00a0weeks from the start of radiotherapy or improvement of subjective or objective clinical symptoms in a period of 4\u00a0weeks from the start of radiotherapy. Predictive factors for overall survival and achieving hemostasis were investigated with the Cox hazards model.ResultsThe median overall survival period was 3.7\u00a0months. Multivariate analysis showed that absence of metastatic disease, higher biological effective dose, higher serum albumin level, lower blood urea nitrogen level and lower neutrophil-to-lymphocyte ratio (NLR) were associated with longer overall survival. Elevation of hemoglobin concentration in a period of 4\u00a0weeks from the start of radiotherapy (mean concentration: 8.2\u00a0g/dL vs. 8.9\u00a0g/dL, p\u2009=\u20090.006) and decrease in the amount of red cell transfusion from a 4-week period before to a 4-week period after the start of radiotherapy (mean amount: 716\u00a0mL vs. 230\u00a0mL, p\u2009<\u20090.0001) were observed. The overall rate of achievement of hemostasis was 59.6%. In multivariate analysis, higher biological effective dose was associated with achievement of hemostasis. Grade 2 or higher acute adverse effects related to radiotherapy were observed in 17.5% of cases in 120 treatment courses. Six cases (5.0%) had grade 3 or 4 adverse effects including gastric penetration in 1 patient and anorexia requiring total parental nutrition in 3 patients. No grade 5 adverse effects were observed.ConclusionsPalliative radiotherapy for gastric cancer bleeding seems to be an effective and safe treatment strategy. Higher treatment dose was associated with longer overall survival and a hemostatic effect. Some hematological parameters may predict overall survival, and they would be helpful for deciding the treatment strategy.",
"genre": "article",
"id": "sg:pub.10.1186/s12904-022-00943-2",
"inLanguage": "en",
"isAccessibleForFree": true,
"isPartOf": [
{
"id": "sg:journal.1028435",
"issn": [
"1472-684X"
],
"name": "BMC Palliative Care",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "1",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "21"
}
],
"keywords": [
"start of radiotherapy",
"gastric cancer bleeding",
"higher biological effective dose",
"longer overall survival",
"overall survival",
"cancer bleeding",
"biological effective dose",
"achievement of hemostasis",
"palliative radiotherapy",
"cell transfusion",
"retrospective study",
"predictive factors",
"treatment strategies",
"adverse effects",
"hemoglobin concentration",
"multivariate analysis",
"red blood cell transfusion",
"higher serum albumin levels",
"median overall survival period",
"multi-institutional retrospective study",
"effective dose",
"blood urea nitrogen levels",
"lower blood urea nitrogen levels",
"objective clinical symptoms",
"blood cell transfusion",
"serum albumin level",
"red cell transfusion",
"total parental nutrition",
"overall survival period",
"safe treatment strategy",
"acute adverse effects",
"urea nitrogen levels",
"Cox hazard model",
"higher treatment dose",
"blood hemoglobin concentration",
"gastric penetration",
"metastatic disease",
"albumin levels",
"lymphocyte ratio",
"clinical symptoms",
"treatment course",
"parental nutrition",
"gastric cancer",
"survival period",
"grade 3",
"effective treatment",
"treatment dose",
"ethical committee",
"hazards model",
"grade 2",
"radiotherapy",
"hemostatic effect",
"hematological parameters",
"bleeding",
"hemostasis",
"patients",
"survival",
"dose",
"weeks",
"overall rate",
"transfusion",
"more reduction",
"elevation",
"period",
"anorexia",
"symptoms",
"start",
"cancer",
"MethodsIn",
"disease",
"course",
"months",
"treatment",
"factors",
"levels",
"effect",
"cases",
"nutrition",
"study",
"Institute",
"approval",
"rate",
"concentration",
"absence",
"Committee",
"strategies",
"reduction",
"analysis",
"nitrogen levels",
"improvement",
"ratio",
"Japan",
"penetration",
"amount",
"achievement",
"model",
"parameters"
],
"name": "Palliative radiotherapy for gastric cancer bleeding: a multi-institutional retrospective study",
"pagination": "52",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1147049122"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1186/s12904-022-00943-2"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"35413824"
]
}
],
"sameAs": [
"https://doi.org/10.1186/s12904-022-00943-2",
"https://app.dimensions.ai/details/publication/pub.1147049122"
],
"sdDataset": "articles",
"sdDatePublished": "2022-06-01T22:25",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220601/entities/gbq_results/article/article_933.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1186/s12904-022-00943-2"
}
]
Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12904-022-00943-2'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12904-022-00943-2'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12904-022-00943-2'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12904-022-00943-2'
This table displays all metadata directly associated to this object as RDF triples.
283 TRIPLES
22 PREDICATES
135 URIs
121 LITERALS
13 BLANK NODES
Subject | Predicate | Object | |
---|---|---|---|
1 | sg:pub.10.1186/s12904-022-00943-2 | schema:about | N04d921e7ebf342d49708ec1693f58e94 |
2 | ″ | ″ | N16ac85c9977847e0835481818ebc2f88 |
3 | ″ | ″ | N489480eb549c4c27b1cd116c06148680 |
4 | ″ | ″ | N6bf9f269922e4411bbc2d29aec36350c |
5 | ″ | ″ | N9f14bc36df99498dbc87122c4f0101de |
6 | ″ | ″ | Nc26c2b68f1d14a9f8a0b42d1bb7f7313 |
7 | ″ | ″ | anzsrc-for:11 |
8 | ″ | ″ | anzsrc-for:1103 |
9 | ″ | ″ | anzsrc-for:1112 |
10 | ″ | schema:author | Nf27cb6abcdc14a34b655fdef0cd247c1 |
11 | ″ | schema:citation | sg:pub.10.1007/s10120-021-01254-w |
12 | ″ | ″ | sg:pub.10.1007/s10388-018-0612-1 |
13 | ″ | ″ | sg:pub.10.1038/bjc.1991.62 |
14 | ″ | ″ | sg:pub.10.1038/bjc.1992.196 |
15 | ″ | ″ | sg:pub.10.1186/s12916-020-01817-1 |
16 | ″ | schema:datePublished | 2022-04-12 |
17 | ″ | schema:datePublishedReg | 2022-04-12 |
18 | ″ | schema:description | BackgroundPalliative radiotherapy for gastric cancer bleeding has been reported to be a safe and effective treatment, but predictive factors for achievement of hemostasis and overall survival have not been established.MethodsIn this retrospective study, 120 courses of palliative radiotherapy for gastric cancer bleeding in 117 patients in 4 institutes in Japan were reviewed with approval of the ethical committee in each institute. The rate of achieving hemostasis was evaluated by 50% or more reduction of red blood cell transfusion before and after the start of radiotherapy, elevation of blood hemoglobin concentration in a period of 4 weeks from the start of radiotherapy or improvement of subjective or objective clinical symptoms in a period of 4 weeks from the start of radiotherapy. Predictive factors for overall survival and achieving hemostasis were investigated with the Cox hazards model.ResultsThe median overall survival period was 3.7 months. Multivariate analysis showed that absence of metastatic disease, higher biological effective dose, higher serum albumin level, lower blood urea nitrogen level and lower neutrophil-to-lymphocyte ratio (NLR) were associated with longer overall survival. Elevation of hemoglobin concentration in a period of 4 weeks from the start of radiotherapy (mean concentration: 8.2 g/dL vs. 8.9 g/dL, p = 0.006) and decrease in the amount of red cell transfusion from a 4-week period before to a 4-week period after the start of radiotherapy (mean amount: 716 mL vs. 230 mL, p < 0.0001) were observed. The overall rate of achievement of hemostasis was 59.6%. In multivariate analysis, higher biological effective dose was associated with achievement of hemostasis. Grade 2 or higher acute adverse effects related to radiotherapy were observed in 17.5% of cases in 120 treatment courses. Six cases (5.0%) had grade 3 or 4 adverse effects including gastric penetration in 1 patient and anorexia requiring total parental nutrition in 3 patients. No grade 5 adverse effects were observed.ConclusionsPalliative radiotherapy for gastric cancer bleeding seems to be an effective and safe treatment strategy. Higher treatment dose was associated with longer overall survival and a hemostatic effect. Some hematological parameters may predict overall survival, and they would be helpful for deciding the treatment strategy. |
19 | ″ | schema:genre | article |
20 | ″ | schema:inLanguage | en |
21 | ″ | schema:isAccessibleForFree | true |
22 | ″ | schema:isPartOf | N1d5ee4ca18c842d18025d006d32026d0 |
23 | ″ | ″ | N555d988214104a7694e672f170120d9f |
24 | ″ | ″ | sg:journal.1028435 |
25 | ″ | schema:keywords | Committee |
26 | ″ | ″ | Cox hazard model |
27 | ″ | ″ | Institute |
28 | ″ | ″ | Japan |
29 | ″ | ″ | MethodsIn |
30 | ″ | ″ | absence |
31 | ″ | ″ | achievement |
32 | ″ | ″ | achievement of hemostasis |
33 | ″ | ″ | acute adverse effects |
34 | ″ | ″ | adverse effects |
35 | ″ | ″ | albumin levels |
36 | ″ | ″ | amount |
37 | ″ | ″ | analysis |
38 | ″ | ″ | anorexia |
39 | ″ | ″ | approval |
40 | ″ | ″ | biological effective dose |
41 | ″ | ″ | bleeding |
42 | ″ | ″ | blood cell transfusion |
43 | ″ | ″ | blood hemoglobin concentration |
44 | ″ | ″ | blood urea nitrogen levels |
45 | ″ | ″ | cancer |
46 | ″ | ″ | cancer bleeding |
47 | ″ | ″ | cases |
48 | ″ | ″ | cell transfusion |
49 | ″ | ″ | clinical symptoms |
50 | ″ | ″ | concentration |
51 | ″ | ″ | course |
52 | ″ | ″ | disease |
53 | ″ | ″ | dose |
54 | ″ | ″ | effect |
55 | ″ | ″ | effective dose |
56 | ″ | ″ | effective treatment |
57 | ″ | ″ | elevation |
58 | ″ | ″ | ethical committee |
59 | ″ | ″ | factors |
60 | ″ | ″ | gastric cancer |
61 | ″ | ″ | gastric cancer bleeding |
62 | ″ | ″ | gastric penetration |
63 | ″ | ″ | grade 2 |
64 | ″ | ″ | grade 3 |
65 | ″ | ″ | hazards model |
66 | ″ | ″ | hematological parameters |
67 | ″ | ″ | hemoglobin concentration |
68 | ″ | ″ | hemostasis |
69 | ″ | ″ | hemostatic effect |
70 | ″ | ″ | higher biological effective dose |
71 | ″ | ″ | higher serum albumin levels |
72 | ″ | ″ | higher treatment dose |
73 | ″ | ″ | improvement |
74 | ″ | ″ | levels |
75 | ″ | ″ | longer overall survival |
76 | ″ | ″ | lower blood urea nitrogen levels |
77 | ″ | ″ | lymphocyte ratio |
78 | ″ | ″ | median overall survival period |
79 | ″ | ″ | metastatic disease |
80 | ″ | ″ | model |
81 | ″ | ″ | months |
82 | ″ | ″ | more reduction |
83 | ″ | ″ | multi-institutional retrospective study |
84 | ″ | ″ | multivariate analysis |
85 | ″ | ″ | nitrogen levels |
86 | ″ | ″ | nutrition |
87 | ″ | ″ | objective clinical symptoms |
88 | ″ | ″ | overall rate |
89 | ″ | ″ | overall survival |
90 | ″ | ″ | overall survival period |
91 | ″ | ″ | palliative radiotherapy |
92 | ″ | ″ | parameters |
93 | ″ | ″ | parental nutrition |
94 | ″ | ″ | patients |
95 | ″ | ″ | penetration |
96 | ″ | ″ | period |
97 | ″ | ″ | predictive factors |
98 | ″ | ″ | radiotherapy |
99 | ″ | ″ | rate |
100 | ″ | ″ | ratio |
101 | ″ | ″ | red blood cell transfusion |
102 | ″ | ″ | red cell transfusion |
103 | ″ | ″ | reduction |
104 | ″ | ″ | retrospective study |
105 | ″ | ″ | safe treatment strategy |
106 | ″ | ″ | serum albumin level |
107 | ″ | ″ | start |
108 | ″ | ″ | start of radiotherapy |
109 | ″ | ″ | strategies |
110 | ″ | ″ | study |
111 | ″ | ″ | survival |
112 | ″ | ″ | survival period |
113 | ″ | ″ | symptoms |
114 | ″ | ″ | total parental nutrition |
115 | ″ | ″ | transfusion |
116 | ″ | ″ | treatment |
117 | ″ | ″ | treatment course |
118 | ″ | ″ | treatment dose |
119 | ″ | ″ | treatment strategies |
120 | ″ | ″ | urea nitrogen levels |
121 | ″ | ″ | weeks |
122 | ″ | schema:name | Palliative radiotherapy for gastric cancer bleeding: a multi-institutional retrospective study |
123 | ″ | schema:pagination | 52 |
124 | ″ | schema:productId | N001564ae5b9d4907a98ffa267bda1e0a |
125 | ″ | ″ | N2f645b7703bb4144a480b35d594fd99f |
126 | ″ | ″ | N55bf7d4e6e67472f92308ccf8ba6230c |
127 | ″ | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1147049122 |
128 | ″ | ″ | https://doi.org/10.1186/s12904-022-00943-2 |
129 | ″ | schema:sdDatePublished | 2022-06-01T22:25 |
130 | ″ | schema:sdLicense | https://scigraph.springernature.com/explorer/license/ |
131 | ″ | schema:sdPublisher | Nf7478c819cff43958c453f522e4d673e |
132 | ″ | schema:url | https://doi.org/10.1186/s12904-022-00943-2 |
133 | ″ | sgo:license | sg:explorer/license/ |
134 | ″ | sgo:sdDataset | articles |
135 | ″ | rdf:type | schema:ScholarlyArticle |
136 | N001564ae5b9d4907a98ffa267bda1e0a | schema:name | pubmed_id |
137 | ″ | schema:value | 35413824 |
138 | ″ | rdf:type | schema:PropertyValue |
139 | N04d921e7ebf342d49708ec1693f58e94 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
140 | ″ | schema:name | Stomach Neoplasms |
141 | ″ | rdf:type | schema:DefinedTerm |
142 | N16ac85c9977847e0835481818ebc2f88 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
143 | ″ | schema:name | Retrospective Studies |
144 | ″ | rdf:type | schema:DefinedTerm |
145 | N1d5ee4ca18c842d18025d006d32026d0 | schema:issueNumber | 1 |
146 | ″ | rdf:type | schema:PublicationIssue |
147 | N2847e5f2889940b5b34dec721e9016b0 | rdf:first | sg:person.01276326705.38 |
148 | ″ | rdf:rest | Nd808de6b86c54a0da485a95e5d9a105c |
149 | N2f645b7703bb4144a480b35d594fd99f | schema:name | doi |
150 | ″ | schema:value | 10.1186/s12904-022-00943-2 |
151 | ″ | rdf:type | schema:PropertyValue |
152 | N36db1ca662a342af992509c96e57b6b7 | rdf:first | sg:person.01247542047.45 |
153 | ″ | rdf:rest | N2847e5f2889940b5b34dec721e9016b0 |
154 | N489480eb549c4c27b1cd116c06148680 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
155 | ″ | schema:name | Hemoglobins |
156 | ″ | rdf:type | schema:DefinedTerm |
157 | N555d988214104a7694e672f170120d9f | schema:volumeNumber | 21 |
158 | ″ | rdf:type | schema:PublicationVolume |
159 | N55bf7d4e6e67472f92308ccf8ba6230c | schema:name | dimensions_id |
160 | ″ | schema:value | pub.1147049122 |
161 | ″ | rdf:type | schema:PropertyValue |
162 | N665cf67e87da40bba1d504c8ac9c144b | rdf:first | sg:person.015230711520.98 |
163 | ″ | rdf:rest | N880e913dfcee496994a442aedfb565d2 |
164 | N6bf9f269922e4411bbc2d29aec36350c | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
165 | ″ | schema:name | Humans |
166 | ″ | rdf:type | schema:DefinedTerm |
167 | N880e913dfcee496994a442aedfb565d2 | rdf:first | sg:person.01214741646.61 |
168 | ″ | rdf:rest | rdf:nil |
169 | N9f14bc36df99498dbc87122c4f0101de | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
170 | ″ | schema:name | Palliative Care |
171 | ″ | rdf:type | schema:DefinedTerm |
172 | Nc26c2b68f1d14a9f8a0b42d1bb7f7313 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
173 | ″ | schema:name | Gastrointestinal Hemorrhage |
174 | ″ | rdf:type | schema:DefinedTerm |
175 | Ncdefbfc4de944b9eb30ee5783449514f | rdf:first | sg:person.01045651705.48 |
176 | ″ | rdf:rest | Nf85d9a84f22048aea69bf96cc843b76b |
177 | Nd3b88a7e77504c509db59b7de3885c7a | rdf:first | sg:person.010746032124.68 |
178 | ″ | rdf:rest | N665cf67e87da40bba1d504c8ac9c144b |
179 | Nd3d5f8f7e348445f9e8e75319e80f7b7 | rdf:first | sg:person.0703105052.65 |
180 | ″ | rdf:rest | Ncdefbfc4de944b9eb30ee5783449514f |
181 | Nd808de6b86c54a0da485a95e5d9a105c | rdf:first | sg:person.0753341500.49 |
182 | ″ | rdf:rest | Nd3d5f8f7e348445f9e8e75319e80f7b7 |
183 | Nde813c428e844c2b82794275c46d17a0 | rdf:first | sg:person.0653677346.82 |
184 | ″ | rdf:rest | N36db1ca662a342af992509c96e57b6b7 |
185 | Nf27cb6abcdc14a34b655fdef0cd247c1 | rdf:first | sg:person.010025651231.08 |
186 | ″ | rdf:rest | Nde813c428e844c2b82794275c46d17a0 |
187 | Nf7478c819cff43958c453f522e4d673e | schema:name | Springer Nature - SN SciGraph project |
188 | ″ | rdf:type | schema:Organization |
189 | Nf85d9a84f22048aea69bf96cc843b76b | rdf:first | sg:person.01240722426.42 |
190 | ″ | rdf:rest | Nd3b88a7e77504c509db59b7de3885c7a |
191 | anzsrc-for:11 | schema:inDefinedTermSet | anzsrc-for: |
192 | ″ | schema:name | Medical and Health Sciences |
193 | ″ | rdf:type | schema:DefinedTerm |
194 | anzsrc-for:1103 | schema:inDefinedTermSet | anzsrc-for: |
195 | ″ | schema:name | Clinical Sciences |
196 | ″ | rdf:type | schema:DefinedTerm |
197 | anzsrc-for:1112 | schema:inDefinedTermSet | anzsrc-for: |
198 | ″ | schema:name | Oncology and Carcinogenesis |
199 | ″ | rdf:type | schema:DefinedTerm |
200 | sg:journal.1028435 | schema:issn | 1472-684X |
201 | ″ | schema:name | BMC Palliative Care |
202 | ″ | schema:publisher | Springer Nature |
203 | ″ | rdf:type | schema:Periodical |
204 | sg:person.010025651231.08 | schema:affiliation | grid-institutes:grid.69566.3a |
205 | ″ | schema:familyName | Takeda |
206 | ″ | schema:givenName | Kazuya |
207 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010025651231.08 |
208 | ″ | rdf:type | schema:Person |
209 | sg:person.01045651705.48 | schema:affiliation | grid-institutes:grid.69566.3a |
210 | ″ | schema:familyName | Ishikawa |
211 | ″ | schema:givenName | Yojiro |
212 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01045651705.48 |
213 | ″ | rdf:type | schema:Person |
214 | sg:person.010746032124.68 | schema:affiliation | grid-institutes:grid.69566.3a |
215 | ″ | schema:familyName | Suzuki |
216 | ″ | schema:givenName | Yu |
217 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010746032124.68 |
218 | ″ | rdf:type | schema:Person |
219 | sg:person.01214741646.61 | schema:affiliation | grid-institutes:grid.69566.3a |
220 | ″ | schema:familyName | Jingu |
221 | ″ | schema:givenName | Keiichi |
222 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01214741646.61 |
223 | ″ | rdf:type | schema:Person |
224 | sg:person.01240722426.42 | schema:affiliation | grid-institutes:grid.69566.3a |
225 | ″ | schema:familyName | Takahashi |
226 | ″ | schema:givenName | Noriyoshi |
227 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01240722426.42 |
228 | ″ | rdf:type | schema:Person |
229 | sg:person.01247542047.45 | schema:affiliation | grid-institutes:None |
230 | ″ | schema:familyName | Kubozono |
231 | ″ | schema:givenName | Masaki |
232 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01247542047.45 |
233 | ″ | rdf:type | schema:Person |
234 | sg:person.01276326705.38 | schema:affiliation | grid-institutes:None |
235 | ″ | schema:familyName | Katagiri |
236 | ″ | schema:givenName | Yu |
237 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01276326705.38 |
238 | ″ | rdf:type | schema:Person |
239 | sg:person.015230711520.98 | schema:affiliation | grid-institutes:grid.69566.3a |
240 | ″ | schema:familyName | Kishida |
241 | ″ | schema:givenName | Keita |
242 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015230711520.98 |
243 | ″ | rdf:type | schema:Person |
244 | sg:person.0653677346.82 | schema:affiliation | grid-institutes:None |
245 | ″ | schema:familyName | Sakayauchi |
246 | ″ | schema:givenName | Toru |
247 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653677346.82 |
248 | ″ | rdf:type | schema:Person |
249 | sg:person.0703105052.65 | schema:affiliation | grid-institutes:grid.69566.3a |
250 | ″ | schema:familyName | Yamamoto |
251 | ″ | schema:givenName | Takaya |
252 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0703105052.65 |
253 | ″ | rdf:type | schema:Person |
254 | sg:person.0753341500.49 | schema:affiliation | grid-institutes:grid.69566.3a |
255 | ″ | schema:familyName | Umezawa |
256 | ″ | schema:givenName | Rei |
257 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0753341500.49 |
258 | ″ | rdf:type | schema:Person |
259 | sg:pub.10.1007/s10120-021-01254-w | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1141419997 |
260 | ″ | ″ | https://doi.org/10.1007/s10120-021-01254-w |
261 | ″ | rdf:type | schema:CreativeWork |
262 | sg:pub.10.1007/s10388-018-0612-1 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1101778605 |
263 | ″ | ″ | https://doi.org/10.1007/s10388-018-0612-1 |
264 | ″ | rdf:type | schema:CreativeWork |
265 | sg:pub.10.1038/bjc.1991.62 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1056443284 |
266 | ″ | ″ | https://doi.org/10.1038/bjc.1991.62 |
267 | ″ | rdf:type | schema:CreativeWork |
268 | sg:pub.10.1038/bjc.1992.196 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1007010292 |
269 | ″ | ″ | https://doi.org/10.1038/bjc.1992.196 |
270 | ″ | rdf:type | schema:CreativeWork |
271 | sg:pub.10.1186/s12916-020-01817-1 | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1132773799 |
272 | ″ | ″ | https://doi.org/10.1186/s12916-020-01817-1 |
273 | ″ | rdf:type | schema:CreativeWork |
274 | grid-institutes:None | schema:alternateName | Department of Radiation Oncology, Ishinomaki Red Cross Hospital, 71 Nishimichishita, Hebita, Ishinomaki, Miyagi, Japan |
275 | ″ | ″ | Department of Radiation Oncology, Miyagi Prefecture Cancer Center, 47-1 Shiote Nodayama, Medeshima, Natori, Miyagi, Japan |
276 | ″ | ″ | Department of Radiation Oncology, Osaki City Hospital, 3-8-1 Furukawa Honami, Osaki, Miyagi, Japan |
277 | ″ | schema:name | Department of Radiation Oncology, Ishinomaki Red Cross Hospital, 71 Nishimichishita, Hebita, Ishinomaki, Miyagi, Japan |
278 | ″ | ″ | Department of Radiation Oncology, Miyagi Prefecture Cancer Center, 47-1 Shiote Nodayama, Medeshima, Natori, Miyagi, Japan |
279 | ″ | ″ | Department of Radiation Oncology, Osaki City Hospital, 3-8-1 Furukawa Honami, Osaki, Miyagi, Japan |
280 | ″ | rdf:type | schema:Organization |
281 | grid-institutes:grid.69566.3a | schema:alternateName | Department of Radiation Oncology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, Japan |
282 | ″ | schema:name | Department of Radiation Oncology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, Japan |
283 | ″ | rdf:type | schema:Organization |